Catherine M. Engelbert is Director at Royalty Pharma plc (RPRX). They have made 3 open-market trades across 1 company since 2020, most recently 2026-06-05.
CIK 0001796439
3 open-market purchases totalling $447K since 2020, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.